# Thomas Bachelot

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/thomas-bachelot/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,142 |
| Field | Advanced Breast Cancer Therapies |
| h-index | 67 |
| i10-index | 175 |
| OpenAlex ID | https://openalex.org/A5041410352 |
| ORCID iD | https://orcid.org/0000-0002-0866-9484 |
| Works | 555 |

## Researcher papers

- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer](https://scholariq.org/papers/tucatinib-trastuzumab-and-capecitabine-for-her2-positive-metastatic-breast/)
- [Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/switch-to-fulvestrant-and-palbociclib-versus-no-switch-in-advanced-breast-cancer/)
- [A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer](https://scholariq.org/papers/a-phase-ii-study-of-abemaciclib-in-patients-with-brain-metastases-secondary-to/)

## Researcher topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.